Bone Biologics (BBLG) Long-Term Debt Issuances (2013 - 2021)
Bone Biologics (BBLG) posted quarterly Long-Term Debt Issuances of $276706.0 for Q3 2021, up 269.97% year-over-year from $74791.0 in Q3 2020, and down 51.39% quarter-over-quarter from $569254.0 in Q2 2021.
Powered by 
Analysis
Bone Biologics (BBLG) Long-Term Debt Issuances (2013 - 2021) Analysis & Trends
Bone Biologics (BBLG) has reported Long-Term Debt Issuances for 7 consecutive years, with $276706.0 the latest figure, recorded in Q3 2021.
- In Q3 2021, Long-Term Debt Issuances rose 269.97% year-over-year to $276706.0; the TTM figure through Dec 2024 stood at $845960.0 (changed N/A YoY), while the FY2024 annual figure was $1.8 million, changed N/A from the prior year.
- Long-Term Debt Issuances eased to $276706.0 in Q3 2021 per BBLG's latest filing, from $569254.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $2.0 million in Q1 2017 and bottomed at $74791.0 in Q3 2020.
- Historically, Long-Term Debt Issuances has averaged $497530.5 across 4 years, with a median of $276706.0 in 2021.
- Annual changes were most pronounced in 2020 — Long-Term Debt Issuances tumbled 92.34% — and 2021, when it jumped 643.15%.
- Bone Biologics' Long-Term Debt Issuances stood at $700000.0 in 2017, then tumbled by 82.86% to $120000.0 in 2019, then retreated by 6.15% to $112623.0 in 2020, then surged by 145.69% to $276706.0 in 2021.
- Business Quant data shows BBLG's Long-Term Debt Issuances at $276706.0 in Q3 2021, $569254.0 in Q2 2021, and $209757.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | - |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 276,706.00 |
| Jun 30, 2021 | 569,254.00 |
| Mar 31, 2021 | 209,757.00 |
| Dec 31, 2020 | 112,623.00 |
| Sep 30, 2020 | 74,791.00 |
| Jun 30, 2020 | 76,600.00 |
| Mar 31, 2020 | 128,165.00 |
| Dec 31, 2019 | 120,000.00 |
| Sep 30, 2019 | 500,000.00 |
| Jun 30, 2019 | 1.00 Mn |
| Mar 31, 2019 | 700,000.00 |
| Sep 30, 2017 | 700,000.00 |
| Mar 31, 2017 | 2.00 Mn |
| Dec 31, 2016 | 1.20 Mn |
| Mar 31, 2016 | 1.88 Mn |
| Dec 31, 2014 | 4.89 Mn |
| Dec 31, 2013 | 529,927.00 |
| Jul 31, 2013 | -4,994.00 |